Aprea Therapeutics Stock Forecast

APRE's stock price has decreased by -60.36% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 4 analysts polled by S&P Global, Aprea Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $4.30. The average 1-year stock price forecast is 489.61% higher than the current stock price, while the lowest is $1.20 (+64.54%) and the highest is $6.00 (+722.71%).

Price Target: $4.30 (+489.61%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$1.20	$4.30	$5.00	$6.00
Change	+64.54%	+489.61%	+585.59%	+722.71%

Analyst Ratings

The average analyst rating for Aprea Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	2	3	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jay Olson Oppenheimer	Oppenheimer	Buy Initiates $5	Buy	Initiates	$5	+585.59%	Jun 15, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Maintains $1.2	Buy	Maintains	$1.2	+64.54%	Jun 1, 2026
Jason McCarthy Maxim Group	Maxim Group	Buy Reiterates $10 → $5	Buy	Reiterates	$10 → $5	+585.59%	May 14, 2026
Robert Driscoll Wedbush	Wedbush	Buy Reiterates $7 → $6	Buy	Reiterates	$7 → $6	+722.71%	May 14, 2026

Financial Forecast

Revenue This Year

535.00K

from 285.76K

87.22%

from 285.76K

Revenue Next Year

1.13M

from 535.00K

111.50%

from 535.00K

EPS This Year

-0.83

from -1.93

EPS Next Year

-0.79

from -0.83

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	583.23K	1.50M	285.76K	535.00K
Revenue Growth	-	-	-	157.63%	-80.98%	87.22%
Gross Profit	-23.90M	-16.40M	-7.04M	-7.86M	-6.76M	535.00K
Gross Margin	-	-	-1,207.80%	-523.16%	-2,364.68%	100.00%
Operating Income	-37.45M	-37.37M	-15.47M	-14.32M	-13.23M	-14.46M
Net Income	-37.13M	-112.66M	-14.29M	-12.96M	-12.60M	-14.12M
EPS	-	-	-	-	-1.93	-0.83
Free Cash Flow	-	-7.97M	-7.67M	-9.27M	-8.56M	-27.63M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	2.1M
Avg	535,000
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	648.9%
Avg	87.2%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.83
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-